Compare Regeneron Pharmaceuticals Inc (REGN) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Under Armour Inc Class A — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while Under Armour Inc Class A trades at $4.79 (market cap $2.15B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 38.8× Under Armour Inc Class A's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| REGN | UA | |
|---|---|---|
Market Cap | $83.43B | $2.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $852.03 | $7.88 |
52-Week Low | $555.51 | $3.96 |
Enterprise Value | $78.14B | $3.13B |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Under Armour (UA) trades at $4.95, down 3.32% amid bearish technical signals and weak fundamentals. The stock shows negative profitability with a net income margin of -9.99% and declining revenue trends. Recent earnings have been mixed, with Q2 2026 beating expectations but Q1 2026 missing. Cash flow remains negative, and the company faces challenges from softer consumer demand in key markets.
The outlook is cautious due to persistent revenue declines and negative margins. While analyst consensus leans slightly bullish with 40.3% buy ratings, significant risks include execution challenges and competitive pressures. Investors should weigh the potential for a turnaround against ongoing operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
